Medtronic PLC $MDT Shares Acquired by Okabena Investment Services Inc.

Okabena Investment Services Inc. raised its holdings in Medtronic PLC (NYSE:MDT) by 394.4% during the third quarter, Holdings Channel reports. The institutional investor owned 16,059 shares of the medical technology company’s stock after buying an additional 12,811 shares during the period. Okabena Investment Services Inc.’s holdings in Medtronic were worth $1,529,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also made changes to their positions in the company. Bedell Frazier Investment Counselling LLC boosted its holdings in Medtronic by 43.5% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 3,297 shares of the medical technology company’s stock valued at $314,000 after purchasing an additional 1,000 shares in the last quarter. New Age Alpha Advisors LLC lifted its position in shares of Medtronic by 92.8% during the 3rd quarter. New Age Alpha Advisors LLC now owns 23,327 shares of the medical technology company’s stock worth $2,127,000 after buying an additional 11,227 shares during the last quarter. APG Asset Management N.V. boosted its holdings in shares of Medtronic by 0.8% in the 3rd quarter. APG Asset Management N.V. now owns 787,721 shares of the medical technology company’s stock valued at $75,023,000 after buying an additional 6,300 shares in the last quarter. Aprio Wealth Management LLC acquired a new position in shares of Medtronic in the 3rd quarter valued at $359,000. Finally, Aviso Financial Inc. grew its position in shares of Medtronic by 7.3% in the 3rd quarter. Aviso Financial Inc. now owns 29,560 shares of the medical technology company’s stock valued at $2,815,000 after buying an additional 2,009 shares during the last quarter. 82.06% of the stock is owned by institutional investors and hedge funds.

Medtronic Trading Up 0.6%

NYSE:MDT opened at $97.60 on Friday. Medtronic PLC has a 12-month low of $79.55 and a 12-month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock’s 50 day simple moving average is $98.93 and its 200-day simple moving average is $96.89. The firm has a market cap of $125.31 billion, a P/E ratio of 27.19, a PEG ratio of 2.45 and a beta of 0.71.

Medtronic (NYSE:MDT) last posted its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.34 by $0.02. The firm had revenue of $9.02 billion for the quarter, compared to analyst estimates of $8.89 billion. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. Medtronic’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the firm posted $1.38 EPS. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts anticipate that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date was Friday, December 26th. Medtronic’s payout ratio is 79.11%.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Positive clinical readout for Altaviva tibial neuromodulation for urinary incontinence — could support future revenue and adoption in restorative/urogynecologic portfolio. Medtronic reports positive findings for Altaviva tibial neuromod
• Positive Sentiment: Analyst coverage remains constructive: consensus “Moderate Buy” and several buy/overweight ratings and raised price targets underpin the stock’s positive bias; company also maintains a steady dividend (annualized ~$2.84, ~2.9% yield). Medtronic PLC Given Average Recommendation of “Moderate Buy” by Analysts
• Neutral Sentiment: Mixed recent share performance and valuation commentary: short-term momentum is cooling (negative returns over recent weeks/months) though 1‑year TSR remains positive — investors are watching whether earnings/guidance sustain the multiple. Assessing Medtronic (MDT) Valuation After Mixed Recent Share Performance
• Neutral Sentiment: Analysis shows MDT has underperformed the S&P 500 over the past year, which may cap sentiment despite company fundamentals — useful context for relative-performance and ETF/sector flows. How Medtronic Impacted The Healthcare Sector on The S&P 500 Chart
• Negative Sentiment: Large insider sale: EVP Harry Skip Kiil sold 52,524 shares (~$5.13M at ~$97.71) and materially reduced his position — raises some investor caution though insiders may sell for personal/liquidity reasons rather than company outlook. Medtronic EVP Harry Skip Kiil Sells 52,524 Shares

Wall Street Analyst Weigh In

MDT has been the topic of several research reports. TD Cowen reaffirmed a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Morgan Stanley raised their price target on Medtronic from $107.00 to $117.00 and gave the stock an “overweight” rating in a research note on Wednesday, November 19th. Daiwa Securities Group reduced their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday. Wells Fargo & Company assumed coverage on shares of Medtronic in a research report on Friday, January 30th. They set an “overweight” rating and a $114.00 target price on the stock. Finally, Needham & Company LLC cut their target price on shares of Medtronic from $121.00 to $120.00 and set a “buy” rating on the stock in a report on Tuesday, February 17th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and ten have given a Hold rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $110.74.

Insider Transactions at Medtronic

In related news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $97.71, for a total transaction of $5,132,120.04. Following the completion of the transaction, the executive vice president directly owned 32,768 shares of the company’s stock, valued at $3,201,761.28. This represents a 61.58% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. 0.26% of the stock is owned by corporate insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).